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A B S T R A C T
Early detection is critical in prevention and treatment of kidney disease. However currently clinical laboratory
and histopathological tests do not provide region-speciﬁc and accurate biomarkers for early detection of kidney
disease. The present study was conducted to identify sensitive biomarkers for early detection and progression of
tubulo-interstitial nephropathy in aristolochic acid I-induced rats at weeks 4, 8 and 12. Biomarkers were
validated using aristolochic acid nephropathy (AAN) rats at week 24, adenine-induced chronic kidney disease
(CKD) rats and CKD patients. Compared with control rats, AAN rats showed anemia, increased serum urea and
creatinine, progressive renal interstitial ﬁbrosis, activation of nuclear factor-kappa B, and up-regulation of pro-
inﬂammatory, pro-oxidant, and pro-ﬁbrotic proteins at weeks 8 and 12. However, no signiﬁcant diﬀerence was
found at week 4. Metabolomics identiﬁed 12-ketodeoxycholic acid, taurochenodesoxycholic acid, LPC(15:0) and
docosahexaenoic acid as biomarkers for early detection of tubulo-interstitial nephropathy. With prolonging
aristolochic acid I exposure, LPE(20:2), cholic acid, chenodeoxycholic acid and LPC(17:0) were identiﬁed as
biomarkers for progression from early to advanced AAN and lysoPE(22:5), indoxyl sulfate, uric acid and
creatinine as biomarkers of advanced AAN. These biomarkers were reversed by treatment of irbesartan and
ergone in AAN rats at week 24 and adenine-induced CKD rats. In addition, these biomarkers were also reversed
by irbesartan treatment in CKD patients.
1. Introduction
Kidney is a common target of environmental and drug toxicity which is
a major clinical problem. Early detection of drug-associated kidney injury
is essential in prevention of kidney disease. Currently, evaluations of
kidney injury are primarily based on measurements of serum creatinine
(Scr) and urea, and routine urinalysis which are not region-speciﬁc and are
signiﬁcantly altered only after substantial kidney injury has occurred.
Serum cystatin C has been considered to be more reliable than Scr and
urinary protein in the early stage of chronic kidney disease (CKD) [1].
However cystatin C is aﬀected by obesity, hyperthyroidism and steroid
therapy. Therefore, region-speciﬁc and accurate biomarkers are needed for
earlier detection of CKD to avoid iatrogenic morbidity and mortality.
Metabolomics is the latest system biology technology for under-
standing complex disease processes. Metabolomics focuses on identi-
ﬁcation of biochemical signatures related to pathogenesis of disease
that could be used for the diagnosis and monitoring of the disease
progression, and response to therapeutic interventions. A number of
metabolomic studies have reported that metabolite changes of serum,
urine and kidney tissues in CKD [2–6]. There has been a lack of
systematic studies simultaneously determining changes in kidney
tissue and serum to establish mechanistic links. Tubulo-interstitial
nephropathy is a common cause of CKD. Aristolochic acid nephropathy
(AAN) is a rapidly progressive interstitial nephritis that can lead to end
stage renal disease (ESRD) [7]. Pharmacological and metabolomic
investigations have revealed that histological lesions and metabolic
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signatures of AAN in experimental animals are similar to those of
human tubulo-interstitial nephropathy [8,9]. Long-term feeding of
adenine to rats causes metabolic abnormalities similar to human
CKD [10,11]. Ultra performance liquid chromatography-quadrupole
time-of-ﬂight high-deﬁnition mass spectrometry (UPLC-QTOF/
HDMS) is regarded as one of the best analytical techniques in
sensitivity, selectivity and reproducibility [12–14]. The present study
was undertaken to examine the eﬀect of AAN on inﬂammatory,
oxidative, and ﬁbrotic cascades in the kidney tissue and to explore
the longitudinal changes in the serum metabolome and kidney
histology with long-term exposure to AAI in rats. Potential biomarkers
were validated using AAN rats at week 24. Biomarkers were further
validated using adenine-induced CKD rats and advanced CKD patients
(Study ﬂowchart in Fig. 1).
2. Materials and methods
2.1. AAN model
Male Sprague-Dawley rats were randomized to the AAN and control
groups. The preparation of the AAN model and blood collections in the
study animals were carried out as described in detail previously [15].
The AAN group was orally administered 20 mg/kg body weight/day of
AAI by oral gavage for 12 weeks and used as the discovery phase.
Serum samples were collected at weeks 4, 8 and 12.
2.2. Validation analysis by AAN rats, adenine-induced CKD rats and
patients with CKD
We validated the biomarkers using the additional independent
groups of control, AAN and irbesartan (IRB)-treated AAN and ergone
(ERG)-treated AAN (ergone, a natural product from Cordyceps sinen-
sis or Polyporus umbellatus) rats at week 24 [16]. In addition, we also
validated the biomarkers using the adenine-induced CKD rats includ-
ing control, CKD and IRB-treated CKD and ERG-treated CKD rats at
week 6.
Blood samples from 25 CKD patients and 25 age and gender-
matched healthy controls were obtained from the Aﬃliated Hospital of
Shaanxi Institute of Traditional Chinese Medicine. The patients were
also treated by irbesartan. The detailed clinical characteristics of the
CKD patient included in this study are summarized in supplementary
Table S1.
All the serum samples were used to test and validate potential
biomarkers identiﬁed in the discovery phase. The biomarkers were
quantitative analysis by using UPLC-QTOF/HDMS. All the study was
approved by the Ethical Committee of Northwest University and
all procedures were conducted in accordance with the Helsinki
Declaration.
2.3. Chemical reagents and antibodies
Aristolochic acid I, creatinine, chenodeoxycholic acid, cholic acid,
taurochenodesoxycholic acid, eicosapentaenoic acid, arachidonic acid
(AA), docosahexaenoic acid, 5-hydroxyeicosatetraenoate (5-HETE),
indoxyl sulfate and uric acid and p-Cresol sulfate were obtained from
the National Institutes for Food and Drug Control. L-tryptophan was
purchased from Amresco Company. Antibodies against nuclear factor-
kappa B (NF-κB), cyclooxygenase-1 (COX-1), 12-lipoxygenase (12-
LPO), NADPH oxidase 4 (NOX4), gp91phox, p67phox, ras-related C3
botulinum toxin substrate 1 (Rac1), plasminogen activator inhibitor-1
(PAI-1), alpha smooth muscle actin (α-SMA), transforming growth
factor-β receptor I (TGF-β RI), transforming growth factor-β receptor
II (TGF-β RII), glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
and histone H3 were purchased from Abcam Company. Antibodies
against inhibitor kappa B alpha (IκBα), phosphorylated inhibitor kappa
B alpha (p-IκBα), transforming growth factor-β 1 (TGF-β1), connective
tissue growth factor (CTGF) and tissue inhibitor of metalloproteinase-1
(TIMP-1) were purchased from Santa Cruz Biotechnology.
2.4. Biochemical, histological and Western blot analyses
Plasma biochemistry was analyzed as described in detail previously
[17]. White blood cell count (WBC), red blood cell count (RBC) or
hemoglobin (HGB) was analyzed by HF-3800 analyzer. Kidney histol-
ogy and ﬁbrotic degree were assessed as described in detail previously
[18]. All the Western blot analyses were performed as described
previously [9].
2.5. Sample preparation and UPLC-MS analysis
Serum samples were prepared as described previously. The UPLC
analysis was performed on a 2.1 mm×100 mm ACQUITY 1.8 µm HSS
T3 using a Waters Acquity™ UPLC system equipped with a Waters
Xevo™ G2 QTof MS. A gradient of 0.1% formic acid in acetonitrile (A)
and 0.1% formic acid in water (B) used as follows: a linear gradient of
0–10 min, 1–99% A; 11.0–12.0 min, 99.0–1.0% A and 12.0–15.0 min,
1% A. The ﬂow rate was 0.45 ml/min. The autosampler was maintained
at 4 °C. The lyophilized serum samples were dissolved in 100 µL of
acetonitrile/water (4:1). Every 2 µL sample solution was injected for
each run.
Mass spectrometry of the optimal conditions were as follows:
capillary voltage of 2.5 kV for negative ion mode, cone voltage of
35 V, desolvation gas temperature of 450 °C, source temperature of
120 °C, desolvation gas ﬂow of 800 L/h, cone gas ﬂow of 30 L/h, The
scan range was from 50 to 1200 m/z. Leucine–enkephalin was used for
accurate mass acquisition. Waters MassLynx v4.1 was used for all the
acquisition and analysis of data.
2.6. Data analysis
The acquired UPLC-HDMS raw data in negative ion mode were ﬁrst
pre-processed by the Progenesis QI and Markerlynx XS. Orthogonal
partial least square-discriminant analysis (OPLS-DA) and principal
component analysis (PCA) was performed to discriminate between
ANN and control groups. The potential metabolites between AAN and
Fig. 1. Flowchart of the study strategy in this study.
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control groups were identiﬁed on the basis of variable importance in
the projection (VIP) on the normalized peak intensity, where metabo-
lites with VIP > 1.0 were selected. A panel of potential metabolites
responsible for the diﬀerence in the AAN group and control group was
obtained.
Fold change (FC) were calculated based on mean ratios for AAN/
control groups. Diﬀerential metabolites between AAN and control
groups were identiﬁed by use of two-tailed Student's t-test (normal
distribution) and two-tailed Mann-Whitney U test (abnormal distribu-
tion) with a threshold of P < 0.05 in the SPSS 19.0 software. The
resultant P values from two-tailed Student's t-test were further
adjusted using the Hochberg and Benjamini false discovery rate
(FDR) method. Potential metabolites with both multivariate and
univariate statistical signiﬁcance (VIP > 1 and P < 0.05) were consid-
ered to be potential biomarkers. Class-speciﬁc metabolomic pattern
was visualized using heat map and z-score plots analyses. In addition,
PLS-DA-based receiver operating characteristics (ROC) analysis was
performed for the selection of candidate biomarkers, and ROC curves
were plotted using MedCalc or SPSS.
2.7. Metabolic network analysis
The related metabolic pathways in AAN rats were performed by
means of the quantitative enrichment analysis algorithm described in
metabolite set enrichment analysis (MSEA) method [19]. Visualization
of the remarkably disturbed metabolic pathways in AAN rats was
performed by MetScape software running on Cytoscape [20].
3. Results
3.1. General data of AAN rats
Compared with the control group, the AAN rats showed a greatly
increasing trend in plasma urea, creatinine and uric acid concentra-
tions as well as WBC at week 4, but did not arrive at statistical
signiﬁcance. However, the AAN group exhibited signiﬁcantly higher
WBC, plasma urea, creatinine, uric acid and phosphorus concentra-
tions, and a signiﬁcantly lower RBC, HGB and plasma calcium
concentrations at weeks 8 and 12 (Fig. 2A)..
Representative photomicrographs of periodic acid-schiﬀ (PAS) and
Masson stained rats’ kidney tissues are shown in Fig. 2B and C. No
signiﬁcant abnormalities were found in the kidneys of the AAN rats at
week 4. In contrast, kidney tissues from the AAN rats exhibited
progressive tubulo-interstitial lesions at weeks 8 and 12. At week 8,
PAS staining showed tubular cell swelling, vacuolization, slight gran-
ular degeneration, and modest monocyte and lymphocyte inﬁltration.
Fig. 2. Clinical biochemical parameters and histological analyses. (A) Serum creatinine, urea, uric acid, calcium and phosphorus of basic serum biochemical parameter and WBC, RBC,
HGB and HCT of basic blood routine parameters comparisons between control and AAN groups. (B) Kidney tissues were stained using PAS method in control group and AAN group at
weeks 4, 8 and 12. (C) Kidney tissues were stained using Masson staining in control group and AAN group at weeks 4, 8 and 12. All values presented as mean ± SD. All statistical
signiﬁcances were calculated by two-tailed Student’s t-test with 95% conﬁdence interval. *P< 0.05, **P < 0.01 compared to control group.
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At week 12, PAS staining showed inﬂammatory cell inﬁltration, tubular
necrosis and atrophy, tubular brush border loss and interstitial ﬁbrosis.
Masson staining of the kidney tissue showed renal interstitial ﬁbrosis,
accumulation of myoﬁbroblasts, and tubular damage at weeks 8 and
12. However, none of these changes were observed in AAN rats at week
4. The morphometric analysis of the kidney tissues revealed signiﬁcant
increase in renal interstitial ﬁbrosis at weeks 8 and 12, but not week 4
in AAN rats.
3.2. Inﬂammatory, oxidative and ﬁbrotic pathways
Expressions of inﬂammatory, oxidative and ﬁbrotic proteins in the
kidney tissues are shown in Fig. 3. Compared to control group, kidney
tissues obtained from the AAN group at weeks 8 and 12 showed a
marked increase in p-IκB and decrease in IκBα as well as elevated
nuclear translocation of NF-κB subunit, indicating activation of NF-κB,
the master regulator of pro-inﬂammatory and pro-ﬁbrotic cytokine and
chemokines. This was accompanied by signiﬁcant up-regulation of pro-
inﬂammatory and ROS-generating molecules including COX-1, 12-
LPO, NOX4, gp91phox, p67phox and Rac1. Activation of inﬂammatory
and oxidative pathways in the kidneys of AAN rats was accompanied by
marked up-regulation of TGF-β RI, TGF-β RII, CTGF, PAI-1, TIMP-1
and α-SMA at weeks 8 and 12, pointing to activation of ﬁbrotic
pathway. However, no signiﬁcant diﬀerence was found in expression
of the measured proteins between AAN and control rats at week 4.
3.3. Metabolic proﬁle and multivariate analysis
We applied UPLC to obtain the metabolic proﬁles in positive and
negative ion modes. We observed that higher noise and matrix eﬀect in
positive ion mode resulted in a higher baseline, so negative ion mode
was applied for ﬁnal analysis (Fig. S1).
To evaluate the systemic changes of metabolome in AAN rats and
ﬁnd biomarkers, a two-predictive component OPLS-DA was performed
on the serum metabolites from control and AAN. The OPLS-DA score
plots could be readily divided into two clusters indicating that serum
metabolic pattern was signiﬁcantly altered in AAN group (Fig. S2A–C).
The metabolic patterns of AAN group at weeks 4, 8 and 12 were plotted
Fig. 3. Western blot analyses of pro-inﬂammatory, pro-oxidant and ﬁbrotic proteins. Western blots analysis between control and AAN groups and protein abundance of p-IκBα, IκBα
and nuclear contents of active subunit of NF-κB, COX-1, 12-LPO and protein abundance of NAD(P)H oxidase subunits (NOX4, Rac1, gp91phox and p67phox) from the renal tissues of
control and AAN groups at weeks 4, 8 and 12. Representative western blots of ﬁbrotic protein including TGF-β RI, TGF-β RII, CTGF, PAI-1, TIMP-1 and α-SMA in the renal tissues of
control and AAN groups at weeks 4, 8 and 12. Box plots for relative optical density of protein expression in control and AAN groups. All statistical signiﬁcances were calculated by two-
tailed Student’s t-test with 95% conﬁdence interval. *P < 0.05, **P < 0.01 compared with the control group.
H. Chen et al. Redox Biology 10 (2016) 168–178
171
by PCA, in which arrows express the variable trend in metabolic
patterns at weeks 0, 4, 8, and 12 (Fig. 4A). This indicated that AAI has
caused diﬀerent metabolic disturbance and pathobiological changes in
diﬀerent stages.
3.4. Selection and identiﬁcation of important diﬀerential metabolites
Initially, variables were selected according to the VIP values from S-
plots, which reﬂect the inﬂuence of each variable in AAN and control
groups. Fig. S2E–G show the S-plots based on serum metabolic
proﬁling at weeks 4, 8, and 12. It was found that 321, 306, and 336
variables have VIP values of greater than 1.0 at weeks 4, 8 and 12,
respectively. Subsequently, using a combination of the Student's t-test
and ROC curve, these variables were selected. Variables that had P <
0.05 and the area under the curve (AUC) value > 0.75 were selected to
further identify potential biomarkers. 150, 114, and 84 variables were
selected at weeks 4, 8 and 12, respectively. PCA and heatmap showed
that these variables could separate AAN from control groups (Fig. S3).
A total of 249 variables with statistically signiﬁcant diﬀerences were
further studied (Fig. 4B). Fig. 4C presents the z-score plots of 150, 114,
and 84 signiﬁcantly changed variables at weeks 4, 8 and 12, respec-
tively. These variables could better reﬂect the metabolic changes of the
kidney injury. To further select the potential biomarkers, two-tailed
Mann-Whitney U test and FDR were also applied to calculate the
signiﬁcance of each identiﬁed metabolite. In addition, xenobiotics,
diﬀerent fragment ions from the same metabolites and variables > 3-
fold diﬀerent between the control groups were excluded. Potential
metabolites were identiﬁed according to the previously reported
method [21]. 13, 17 and 18 diﬀerential metabolites were identiﬁed
as potential biomarkers at weeks 4, 8 and 12, respectively (Table 1).
3.5. Biomarkers of progressive AAN
LysoPE(20:2), cholic acid (CA), chenodeoxycholic acid (CDCA),
cystathionine sulfoxide and lysoPC(17:0) were signiﬁcantly altered in
AAN rats at weeks 4, 8 and 12. To identify biomarkers indicative of
progressive AAN from early stage to advanced stage during the course
of the AAN, a criterion was applied for selecting identiﬁed metabolites
that were unidirectionally changed across the diﬀerent AAN stages.
Metabolites that were increased in one stage and decreased in another
stage were not selected. By applying this selection criterion, a subset of
three metabolites including lysoPE(20:2), CA and CDCA were consis-
tently increased with AAN progression, whereas lysoPC(17:0) tended to
consistently decrease with AAN progression from control to early stage
to advanced stage (Fig. 4D and E). PCA shows that AAN subgroups and
control group can be clearly separated (Fig. 4F). Therefore these
metabolites could potentially serve as biomarkers for progressive AAN.
3.6. Early biomarkers of AAN
Metabolites showed early response in AAN rats (4th week).
Interestingly, the rise in taurochenodesoxycholic acid (TCDCA), AA and
12-ketodeoxycholic acid (12-KDCA) as well as the decline in lysoPC(15:0),
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) were
observed in AAN rats prior to detectable changes in conventional chemical
markers and histological evidence of kidney injury (Fig. 5A). The
alterations of these metabolites were most dramatic at the early time
point, and less pronounced at the advanced AAN and as such represent
potential biomarkers for the early detection of AAN.
The suitability of the identiﬁed metabolites for use as biomarkers of
early kidney injury was examined by ROC analysis (Fig. 5B and C). Six
metabolites had an AUC of more than 0.75 and were superior to
standard biomarker creatinine for detecting early renal injury. Among
these identiﬁed potential candidates, 12-KDCA, lysoPC(15:0), TCDCA
and DHA had high predictive performance and had high sensitivity and
speciﬁcity. Although AA and EPA had high AUC value, their sensitivity
or speciﬁcity was low and as such they were excluded. Therefore, four
metabolites could be used as eﬀective serum biomarkers for the early
detection of renal injury.
3.7. Biomarkers of advanced AAN
LysoPE(22:5), indoxyl sulfate, uric acid and creatinine were found
at week 12 only. PCA and heatmap showed that the AAN and control
groups could be separated completely based on these biomarkers
(Fig. 5D and E). The suitability of the four metabolites for use as
biomarkers of advanced AAN was examined by ROC analysis (Fig. 5F).
In addition to the current standard biomarker, Scr and uric acid,
lysoPE(22:5) and indoxyl sulfate were identiﬁed as the top-ranked
candidates, with an AUC of more than 0.94. Thus indoxyl sulfate and
lysoPE(22:5) could be regarded as biomarkers of advanced AAN.
3.8. Biomarkers validation by advanced AAN rats at 24 weeks
To conﬁrm the usefulness of candidate biomarkers of advanced
AAN, serum proﬁle of control, AAN and drug-treated AAN rats was
analyzed at week 24. Similar to AAN rats at week 12 subgroup of AAN
rats at week 24 showed signiﬁcantly increased lysoPE(22:5), CDCA,
lysoPE(20:2), CA, creatinine, indoxyl sulfate and uric acid as well as
signiﬁcantly increased lysoPC(17:0) with high sensitivity and speciﬁcity
(Table S1). AAN rats had improved renal function (Fig. 6A) and
reversed 8 biomarkers (Fig. 6B) by oral administration each day
continuously for 24 weeks. Biomarker validation showed that these
biomarkers were associated with only the disease state and had very
few interference from the non-disease factors.
3.9. Biomarkers validation by adenine-induced CKD rats
In order to determine whether the biomarkers found in AAN rats
are shared with another model of chronic tubulo-interstitial nephro-
pathy, serum biochemistry, renal histology, protein expression and
serum metabolomics were obtained in rats with CKD at week 8.
Adenine-induced CKD rats had improved renal function (Fig. 6C),
renal histology (Fig. 6D), lower expression of NF-κB and α-SMA
(Fig. 6E) by drug treatment compared to CKD rats. Similar to AAN
rats, CKD rats showed elevation of lysoPE(22:5), indoxyl sulfate, CA,
creatinine, lysoPE(20:2) and CDCA (Fig. 6F). In addition uric acid level
did not reach statistical signiﬁcance (P=0.503). Interestingly unlike the
AAN rats, rats with adenine-induced CKD showed a signiﬁcant increase
in serum lysoPC(17:0) (Fig. 6F). In addition to the current standard
biomarkers creatinine, AUC values of ﬁve biomarkers were equal to or
greater than 0.87 and had high sensitivity and speciﬁcity (Table S2).
Eight biomarkers in CKD rats were reversed by drug treatment
(Fig. 6F). Nevertheless, the identiﬁed metabolic signature demon-
strated a concerted dysregulation of the metabolic pathways similar
to AAN rats. The results showed that such abnormal metabolic changes
were a common feature of chronic interstitial nephropathy of diverse
etiologies.
3.10. Biomarkers validation by patients with CKD
In order to examine whether eight potential biomarkers found in
AAN rats are relevant to human CKD, serum samples from healthy
controls, CKD patients and IBR-treated CKD patients were analyzed
using UPLC-QTOF/HDMS. Irbesartan had improved renal histology of
CKD patients (Fig. 6G). Results of the metabolic proﬁles showed that
like AAN rats, indoxyl sulfate, lysoPE(22:5), creatinine, lysoPE(20:2),
CDCA and CA were elevated in CKD patients. Although not statistically
signiﬁcant, lysoPC(17:0) and uric acid showed a trend of elevation
(Table 2 and Fig. 6H). These biomarkers were reversed by treatment of
irbesartan. Six biomarkers including indoxyl sulfate, lysoPE(22:5),
creatinine, lysoPE(20:2), CDCA and CA had high AUC values ( >
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Table 1
Identification biomarkers of AAN detected by UPLC-QTOF/HDMS in negative ion mode in the 4th, 8th and 12th week.
No. Metabolite VIPa FCb Pc Pd FDRe Metabolic pathway
4th week
1 LysoPC(15:0) 4.15 0.74 1.21E−04 5.88E−04 1.75E−04 Lipid metabolism
2 LysoPC(17:0) 3.71 0.82 4.78E−03 3.57E−02 4.78E−03 Lipid metabolism
3 Chenodeoxycholic acid 3.51 1.99 3.58E−04 7.71E−04 3.88E−04 Bile acid metabolism
4 LysoPE(20:2) 3.22 1.37 4.76E−05 7.78E−04 8.84E−05 Lipid metabolism
5 Cholic acid 2.93 1.61 1.12E−04 1.60E−03 1.82E−04 Bile acid metabolism
6 Taurochenodesoxycholic acid 2.74 2.06 2.90E−05 4.75E−04 6.28E−05 Bile acid metabolism
7 Eicosapentaenoic acid 2.56 0.71 6.54E−11 4.49E−06 4.25E−10 fatty acid metabolism
8 Arachidonic acid 2.47 3.48 6.69E−07 9.48E−06 2.17E−06 Prostaglandin and leukotriene metabolism
9 7-Ketodeoxycholic acid 2.24 0.67 1.90E−04 3.39E−05 2.47E−04 Bile acid metabolism
10 Cystathionine sulfoxide 2.06 0.54 2.56E−05 7.78E−04 6.66E−05 Progestational hormone metabolism
11 16-Dehydroprogesterone 1.77 1.95 6.24E−16 4.13E−06 8.11E−15 Progestational hormone metabolism
12 Docosahexaenoic acid 1.65 5.43 8.42E−08 4.73E−06 3.65E−07 fatty acid metabolism
13 12-Ketodeoxycholic acid 1.26 0.74 2.75E−04 3.64E−06 3.25E−04 Bile acid metabolism
8th week
1 5-HETE 3.91 0.58 1.30E−07 4.87E−07 1.11E−06 Arachidonic acid metabolism
2 LysoPE(20:1) 3.37 1.46 7.17E−06 2.95E−07 1.74E−05 Lipid metabolism
3 Chenodeoxycholic acid 3.18 2.27 5.48E−04 6.25E−03 9.32E−04 Bile acid metabolism
4 7-Ketodeoxycholic acid 3.15 4.54 2.85E−06 1.64E−06 1.21E−05 Bile acid metabolism
5 Tryptophan 2.96 0.55 1.09E−09 7.23E−07 1.85E−08 Tryptophan metabolism
6 2-Methylacetophenone 2.72 4.15 1.91E−07 1.34E−04 1.08E−06 Unknown
7 Cholic acid 2.52 1.69 1.55E−02 1.17E−02 1.55E−02 Bile acid metabolism
8 LysoPE(24:6) 2.42 1.77 1.17E−02 6.35E−03 1.33E−02 Lipid metabolism
9 LysoPE(20:2) 2.39 1.36 6.35E−03 3.28E−03 7.71E−03 Lipid metabolism
10 LysoPC(17:0) 2.17 0.74 3.28E−03 7.78E−04 4.29E−03 Lipid metabolism
11 LysoPE(18:0) 1.87 1.41 7.78E−04 2.76E−03 1.20E−03 Lipid metabolism
12 LysoPE(22:4) 1.76 1.41 1.64E−03 2.64E−03 2.32E−03 Lipid metabolis
13 Leukotriene A4 1.54 0.49 2.42E−05 9.36E−06 5.14E−05 Prostaglandin and leukotriene metabolism
14 LysoPE(18:1) 1.44 1.84 5.69E−06 7.08E−07 1.61E−05 Lipid metabolism
15 Glycocholic acid 1.32 0.52 3.89E−06 3.00E−07 1.32E−05 Bile acid metabolism
16 Dihydroxy-3-oxo-4-cholenoic acid 1.29 5.15 8.97E−05 3.31E−05 1.69E−04 Bile acid metabolism
17 Cystathionine sulfoxide 1.27 0.79 1.17E−02 3.56E−02 1.24E−02 Progestational hormone metabolism
12th week
1 LysoPE(18:0) 4.67 1.99 8.66E−07 2.14E−05 5.20E−06 Lipid metabolism
2 5-HETE 4.49 0.82 6.80E−06 2.68E−06 1.11E−05 Arachidonic acid metabolism
3 LysoPC(17:0) 3.97 0.67 1.04E−06 7.71E−04 4.68E−06 Lipid metabolism
4 LysoPE(20:2) 3.75 1.81 3.30E−09 7.78E−04 5.94E−08 Lipid metabolism
5 Indoxyl sulfate 3.57 4.37 1.06E−06 2.40E−06 3.82E−06 Tryptophan metabolism
6 LysoPE(20:1) 3.26 1.54 1.17E−06 2.50E−05 3.51E−06 Lipid metabolism
7 LysoPC(15:0) 2.98 0.91 5.93E−04 4.97E−03 7.12E−04 Lipid metabolism
8 Leukotriene A4 2.93 0.57 1.92E−06 2.54E−05 4.94E−06 Prostaglandin and leukotriene metabolism
9 Uric acid 2.81 2.20 1.46E−03 5.28E−03 1.64E−03 Adenine metabolism
10 LysoPE(24:6) 2.76 1.62 5.14E−05 3.78E−05 7.71E−05 Lipid metabolism
11 Creatinine 2.53 1.52 7.13E−03 6.24E−03 7.55E−03 Arginie and proline metabolism
12 LysoPE(18:1) 2.31 1.84 4.35E−06 1.05E−05 8.70E−06 Lipid metabolism
13 Cholic acid 2.2 2.16 2.21E−04 3.23E−03 2.84E−04 Bile acid metabolism
14 Chenodeoxycholic acid 1.86 3.06 1.55E−07 7.78E−04 1.40E−06 Bile acid metabolism
15 Cystathionine sulfoxide 1.53 0.84 2.20E−02 3.54E−02 2.20E−02 Progestational hormone metabolism
16 LysoPE(16:0) 1.47 1.74 4.80E−06 2.50E−04 8.64E−06 Lipid metabolism
17 LysoPE(22:5) 1.34 2.13 5.90E−05 1.84E−04 8.17E−05 Lipid metabolism
18 Taurochenodesoxycholic acid 1.21 0.4 3.42E−06 5.81E−07 7.70E−06 Bile acid metabolism
a VIP was obtained from OPLS-DA model with a threshold of 1.0.
b FC was obtained by comparing those identiﬁed metabolites in AAN rats with control rats. FC with a value > 1 indicated a relatively higher intensity present in AAN rats, whereas a
value < 1 indicated a relatively lower intensity compared with control rats.
c P values from Student’s t-test.
d P values from Mann-Whitney U-test.
e FDR value was obtained from the adjusted P value of FDR correction by Benjamini-Hochberg method.
Fig. 4. Metabolomic proﬁling of AAN. (A) The PCA score scatter plot of the diﬀerent AAN at weeks 4, 8 and 12. (B) Vann diagram of the total remarkable variables when the AAN and control
groups were compared (VIP>1.0, P<0.01, AUC>0.85). (C) Z-score plots for the data of 150 (week 4), 114 (week 8) and 84 (week 12) variables normalized to the mean of the control group. (D)
Heat map of ﬁve metabolites at weeks 4, 8 and 12. The metabolites occur in AAN rats at weeks 4, 8 and 12. The color of each section is proportional to the signiﬁcance of change of metabolites (red,
upregulated; green, downregulated). Rows: metabolites; Columns: samples. (E) Comparison of the relative intensity of ﬁve metabolites including lysoPE(20:2), CA, CDCA, cystathionine sulfoxide
and lysoPC(17:0). These metabolites were signiﬁcantly increased or decreased on AAN progression from early stage to advanced stage. These metabolites could potentially serve as biomarkers for
progressive AAN. (F) PCA score plot based on the ﬁve metabolites of the control group and AAN group. All statistical signiﬁcances were calculated by two-tailed Student’s t-test with 95% conﬁdence
interval. *P<0.05, **P<0.01 compared to the control group. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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0.84) as well as high sensitivity and speciﬁcity (Fig. 6I and Table 2).
The AUC value of the combination of the eight biomarkers was larger
than each individual biomarker (Fig. 6J). To predict class probabilities
for each sample, validation was performed on eight potential biomar-
kers (Fig. 6K). 22 out of the 25 patients with CKD were correctly
grouped (88% sensitivity). 24 out of the 25 healthy controls were
located in the control area (96% speciﬁcity). PCA showed CKD patients
could be separated from controls (Fig. 6L). These results indicated that
these metabolites were important metabolic biomarkers which can
distinguish the CKD patients from healthy subjects and as such could
serve as suitable serum biomarkers of chronic tubulo-interstitial
nephropathy. Metabolic pathway analysis revealed that these biomar-
kers were associated with purine metabolism, arginine and proline
metabolism, glycerophospholipid metabolism and primary bile acid
biosynthesis (Fig. 6M and N).
4. Discussion
AAN is a rapidly progressive tubulo-interstitial nephropathy.
Metabolomics approach was employed in rats with AAN and diﬀerential
metabolites were identiﬁed. MSEA revealed altered metabolic pathways in
AAN rats (Figs. S4, S5 and S6). A total of 27 metabolites were associated
with metabolisms of lipids, amino acids and purine metabolism. Some of
these metabolites were identiﬁed as potential biomarkers to discriminate
the early and advanced stages of CKD (Fig. S7).
Using a zebra ﬁsh model, a recent study revealed that AAI-induced
renal injury was associated with oxidative stress and inﬂammation as
evidenced by increased gene expression of pro-inﬂammatory molecules
such as cyclooxygenase, myeloperoxidase and tumor necrosis factor
alpha mRNA expression [22]. Using cultured glomerular mesangial
cells, another study demonstrated that AAI up-regulated CTGF expres-
sion which could be suppressed by increased inducible nitric oxide
synthase-derived nitric oxide [23]. Using cultured human HK-2 cells,
the study showed that exposure to AAI led to a dose-dependent
increased reactive oxidative species production, glutathione depletion
and cell death [24]. Another study showed that administration of a
synthetic nuclear factor-erythroid-2-related factor 2 activator amelio-
rated aristolochic acid-induced renal injury [25]. These ﬁndings
illustrated that AAN is closely associated with oxidative stress and
inﬂammation.
Earlier studies have demonstrated the importance of plasma
phospholipid abnormalities in renal injury [26]. Phospholipids have
been reported to be biomarkers for chronic glomerulonephritis, chronic
renal failure, ESRD and diabetic nephropathy [26]. Plasma metabo-
lomics have been employed in pathophysiology of AAI-induced renal
injury and lysoPC(20:5) and lysoPC(20:4) have been identiﬁed as
potential biomarkers in AAN rats [27]. We also found phospholipids to
be the most important metabolites. Lipids accounted for 85%, 76% and
72% of all identiﬁed metabolites at weeks 4, 8, and 12, respectively.
These ﬁndings indicated that lipids were aﬀected in diﬀerent stages of
AAN. The underlying mechanism of the observed disturbances of lipids
is not completely clear. As noted above, oxidative stress and inﬂamma-
tion play a major role in the pathogenesis of AAN by promoting
generation of reactive oxygen, nitrogen, and halogen species which
attack and denature lipids, proteins and nucleic acid and deplete anti-
oxidant defense system [28]. In fact nephrotoxic drugs have been
shown to increase the lipid peroxidation product, malondialdehyde and
reduced catalase, glutathione, glutathione peroxidase and superoxide
dismutase levels in the kidney tissue [26]. In addition, patients with
renal injury exhibit oxidative stress which is marked by increased pro-
oxidants and impairment of the antioxidant capacity, factors which
contribute to tissue damage and upregulation of pro-ﬁbrotic pathways
[29]. In presence of oxidative stress, free radicals activate phospholi-
pase A2, which hydrolyses phosphatidylcholine to produce LysoPC.
This phenomenon may explain the observed increase in LysoPE and
LysoPC in our AAN rats.
Bile acids are produced from conjugation of cholesterol and its
incorporation in the bile by the liver for secretion in the intestine. Within
the intestine, particularly colon, bile acids are deconjugated, oxidized
and dehydroxylated by bacterial ﬂora forming secondary bile acids which
are transported back to the liver where they can be further modiﬁed to
form tertiary bile acids. Plasma concentration of bile acids rises and
kidney became the sole route of their excretion in patients and animals
with obstructive jaundice in whom bile acids may have nephrotoxic
eﬀects [30]. CDCA is the primary bile acid, and 7-ketolithocholic acid is
the major intermediate byproduct of the intestinal bacterial conversion
of CDCA to ursodeoxycholic acid. Compared with control group, serum
bile acids including CDCA, CA, TCDCA, 7-ketodeoxycholic acid (7-
KDCA) and 12-KDCA were signiﬁcantly increased in our AAN rats. It
was reported that increased 12-KDCA concentration was observed in 5/
6 nephrectomized CKD rats [31]. Recent studies have revealed dramatic
changes in the composition and function of the gut microbiome in
humans and experimental animals with renal failure [32,33], events that
can signiﬁcantly alter bile acid metabolism in presence of renal disease.
In fact elevation of plasma bile acids is mainly due to the expansion of
small-intestinal bacteria capable of deconjugating bile acids and thereby
facilitating their absorption. It has been reported that plasma 3-
oxocholic acid and 7-KDCA are signiﬁcantly increased in rats with AA-
induced renal injury [27] and elevated plasma bile acids work in concert
with other risk factors in exacerbating kidney disease [30]. The bile acid
metabolites including CDCA, CA, deoxycholic acid and ursodeoxycholic
acid have been identiﬁed in the serum and dialysate eﬄuent of
hemodialysis patients. The pre-dialysis and post-dialysis serum concen-
trations of secondary bile acids have been shown to be signiﬁcantly
higher in ESRD patients than in healthy subjects [34,35]. Patients with
CKD have been reported to exhibit alteration in the bile acid balance.
Total serum bile acids are consistently elevated in patients with diﬀerent
stages of CKD or after kidney transplantation [36]. The observed
changes in plasma bile acids in AAN may be due to alteration of
synthesis and secretion of bile acids, and conﬁrm the eﬀect of kidney
disease on bile acid metabolism [37].
Administration of the farnesoid X receptor agonist, CDCA, attenu-
ated proteinuria, mesangial expansion, and tubulo-interstitial ﬁbrosis
and diminished up-regulation of collagen IV, TGF-β, PAI-I, α-SMA,
tumor necrosis factor alpha. interleukin 6, and NAD(P)H oxidase in the
renal cortex of high-fructose-fed Wistar rats [38]. Renal interstitial
ﬁbrosis and inﬂammation and oxidative stress observed in the AAN
rats employed in the present study were accompanied by marked
changes in bile acid metabolites. Given the well demonstrated action of
bile acid metabolites in regulation of oxidative, inﬂammatory and
ﬁbrotic pathways, the observed changes in bile acid metabolism may
contribute to the renal injury in this model.
Fig. 5. Box-and-whisker plot analysis and ROC analysis based on PLS-DA models of early kidney injury biomarkers. (A) Combined box-and-whisker and dot plot of normalized intensity
of six metabolites (lysoPC(15:0), TCDCA, AA, EPA, DHA, 12-KDCA) of control and AAN groups. Box-and-whisker and dot plot illustrated signiﬁcant changes in the levels of identiﬁed
early biomarkers between control and AAN groups at week 4. Signiﬁcant increases TCDCA, AA and 12-KDCA were observed in the AAN group, accompanied by concomitant decrease
lysoPC(15:0), EPA and DHA displayed the opposite trends in association with early kidney injury. (B) ROC curve of the diagnostic performance of the six identiﬁed biomarkers. ROC
analysis was employed to quantify the diagnostic performance of these biomarkers, yielding an AUC and sensitivity of each identiﬁed metabolite from control and AAN groups at week 4
(C). *P < 0.05, **P< 0.01. Hierarchical cluster analysis and ROC curves of ﬁve diﬀerential biomarkers in advanced AAN. (D) PCA of four diﬀerential biomarkers including uric acid,
lysoPE(22:5), indoxyl sulfate and creatinine only appeared at week 12. The AAN and control could be separated completely based on these four diﬀerential biomarkers. (E) Clustered
heatmap of four diﬀerential biomarkers only appeared at week 12. These biomarkers showed a response on advanced AAN. (F) ROC curves analysis. ROC curves for the individual
metabolites with high sensitivity and speciﬁcity from four biomarkers. The AUC, 95% conﬁdence interval, sensitivity and speciﬁcity for four biomarkers were mentioned.
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Fig. 6. Validation of diﬀerential biomarkers by animal models and CKD patients. (A) Levels of serum creatinine and urea in control, AAN and drug-treated rats at week 24. (B)
Comparison of the relative intensity of 8 metabolites in control, AAN and drug-treated rats at week 24. These metabolites were also signiﬁcantly increased or decreased in AAN rats at
week 24. These metabolites were reversed by treatment with irbesartan and ergone. (C) Levels of serum creatinine and urea in control, CKD and drug-treated rats at week 6. (D)
Irbesartan ameliorated ﬁbrosis development in adenine-induced CKD rats. Representative images of H&E, masson, TGF-β1, and α-SMA staining of kidney section from control, CKD
and drug-treated rats. (E) Protein expression of NF-κB and α-SMA in the renal tissues of control, CKD and drug-treated rats. (F) Comparison of the relative intensity of 8 metabolites in
control, CKD and drug-treated rats. (G) Representative images of masson staining of kidney section from CKD patients. (H) Comparison of the relative intensity of 8 metabolites in
control, CKD and drug-treated patients. (I) ROC curves for the diagnosis of chronic renal injury with the individual biomarkers and the combination of the eight (all eight) in CKD
patients. (J) ROC curves for the diagnosis of chronic renal injury with the combination of the eight biomarkers. (K) Diagnostic performance of the potential biomarkers based on the
PLS-DA model. Black dots represent CKD patients, and black circles represent healthy controls. The black dots with red squares and black circles with red squares are for the incorrectly
predicted samples in CKD patient and controls, respectively. (L) PCA score plot based on the eight potential biomarkers in CKD patients and controls. (M) Summary of ingenuity
pathway analysis with MetPA including purine metabolism, arginine and proline metabolism, glycerophospholipid metabolism and primary bile acid biosynthesis. The size and color of
each circle was based on pathway impact value and p-value, respectively. (N) Metabolic pathways were visualized by means of cytoscape software. Metabolic pathways included purine
metabolism and primary bile acid biosynthesis of CKD patients. The biomarkers in our study were represented by red hexagons. Hexagons with green lines mean that the alteration of
the biomarkers in CKD had statistical signiﬁcance. The size of hexagons indicated the FC of the corresponding metabolite in CKD relative to controls. In addition, pink hexagons
indicated metabolites participating in the metabolic pathway but not been detected in our study. (For interpretation of the references to color in this ﬁgure legend, the reader is referred
to the web version of this article.)
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Table 2
Analyses of statistically significant differences and ROC curve of biomarkers validation in patients with advanced CKD.
Metabolite Pa Pb FDRc AUC Sensitivity (%) Specificity (%) 95%Cl
Indoxyl sulfate 3.90E−07 1.98E−06 7.80E−07 0.89 86.5 89.7 0.80−0.97
LysoPE(0:0/22:5) 2.39E−07 4.88E−06 6.37E−07 0.88 82.5 91.4 0.78−0.97
Creatinine 2.02E−07 4.88E−06 8.08E−07 0.88 92.4 83.6 0.78−0.97
LysoPE(20:2/0:0) 5.71E−06 1.01E−05 7.61E−06 0.86 0.91 0.85 0.76−0.96
Chenodeoxycholic acid 1.15E−06 1.61E−05 1.84E−06 0.86 0.85 0.89 0.75−0.96
Cholic acid 1.99E−07 4.05E−05 1.59E−06 0.84 0.78 0.87 0.73−0.94
LysoPC(17:0) 1.11E−01 2.99E−01 1.27E−01 0.58 0.72 0.54 0.43−0.73
Uric acid 2.11E−01 3.99E−01 2.11E−01 0.56 0.64 0.52 0.39−0.72
a P values from Student's t-test.
b P values from Mann-Whitney U test.
c FDR value was obtained from the adjusted P value of FDR correction by Benjamini-Hochberg method.
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